Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
13.00
-0.33 (-2.48%)
Dec 20, 2024, 4:00 PM EST - Market closed
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
158.33M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.79B |
Nutex Health | 292.00M |
Adaptimmune Therapeutics | 175.04M |
Sutro Biopharma | 160.96M |
Seres Therapeutics | 126.33M |
Pro-Dex | 56.80M |
Nanobiotix | 45.22M |
Cellectis | 36.04M |
CRBP News
- 12 days ago - Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - GlobeNewsWire
- 18 days ago - FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies - Seeking Alpha
- 7 weeks ago - Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference - GlobeNewsWire
- 2 months ago - Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit - GlobeNewsWire
- 3 months ago - Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now - Benzinga
- 4 months ago - Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say - Market Watch